Early Phase 1
Completed N=16
Study of the Effect of Sitagliptin on Glucose (Sugar) Metabolism in Patients With Heart Failure
Heart Failure, Congestive
Source: ClinicalTrials.gov NCT00657280 ↗
Enrolled (actual)
16
Serious AEs
0.0%
Results posted
Dec 2014
Primary outcomePrimary: Determine the Effects of Sitagliptin on Myocardial Glucose Uptake Measured by Myocardial PET Scan — 3.4; 4.1 SUV
Summary
This study will investigate the effects of sitagliptin, a medicine commonly used to treat type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure which is not due to heart attacks. We hope to determine whether improving the heart's ability to use glucose in the blood may help improve the function of the heart as well. If so, this may suggest that even people who do not have frank diabetes but who do have heart failure may benefit from using this medication.
This study will also investigate the effect of sitagliptin on the body's use of sugar, and of the effect of sitagliptin on blood flow to the heart.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Determine the Effects of Sitagliptin on Myocardial Glucose Uptake Measured by Myocardial PET Scan |
3.4; 4.1 | — |
| PRIMARY Determine the Effects of Sitagliptin on Myocardial Glucose Uptake in Patients With Nonischemic Cardiomyopathy |
— | — |
| SECONDARY Determine the Effects of Sitagliptin on Microvascular Function in Patients With Nonischemic Cardiomyopathy |
— | — |
| SECONDARY Determine the Effects of Sitagliptin on Microvascular Function in Patients With Nonischemic Cardiomyopathy |
— | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosis of nonischemic dilated cardiomyopathy, current NYHA class I-III congestive heart failure
- Treatment with a stable comprehensive heart failure regimen for at least 3 months (including beta-blockers and ACE-inhibitors or angiotensin receptor blockers unless intolerant)
- Age > 18 yrs
Exclusion Criteria
- Cardiomyopathy primarily due to one of the following:
- Ischemic heart disease
- Primary valvular lesion
- Hypertrophic cardiomyopathy
- Cardiac resynchronization within the last 3 months
- Calculated creatinine clearance 125 mg/dl
- History of heart transplantation
- Pregnancy or active breast feeding
- Hospitalization for decompensated heart failure within 30 days prior to enrollment.
Data sourced from ClinicalTrials.gov (NCT00657280). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.